Special Issue

Blood-Brain-Barrier-Penetrating Therapeutics Targeting Intrinsically Disordered Proteins in Neurodegenerative Diseases

Message from the Guest Editor

Intrinsically disordered proteins (IDPs) hold tremendous potential for therapeutic interventions of neurodegenerative diseases. There is a need to call for the use of novel strategies and approaches to advance the development of IDP-targeting therapeutics. The molecular mechanisms of action of typical drug-like candidates include (i) shifting IDP conformational ensembles, (ii) the disassembly of intermediate toxic oligomeric species, and (iii) the inhibition of proteinprotein interactions and distortions of IDP functional complexes. Importantly, the highly restrictive nature of the blood-brain barrier (BBB) represents a major hurdle to advance brain-targeting drugs, which necessitates the development of new therapeutics with BBBpenetrating capability. We invite authors to submit original articles and review articles highlighting the latest developments of BBB-penetrating therapeutics targeting IDPs in neurodegenerative diseases.

Guest Editor

Dr. Chih Hung Lo

Department of Biology and Interdisciplinary Neuroscience Program, Syracuse University, Syracuse, NY, USA

Deadline for manuscript submissions

closed (10 April 2025)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/214570

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

